Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Gastric Cancer
•
Esophageal Cancer
•
Medical Oncology
•
Gastroesophageal Cancer
How do you manage postoperative residual disease after neoadjuvant chemoradiotherapy and surgery for a patient with locally advanced esophageal or GE junction adenocarcinoma?
Related Questions
What are your top takeaways from ASCO GI 2026?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?
What is the preferred second-line therapy for HER2-positive patients with esophageal squamous cell carcinoma who have progressed on first line Trastuzumab and Immunotherapy?
What adjuvant treatment would you give to a locally advanced esophageal adenocarcinoma status post neoadjuvant FLOT s/p resection with positive margins?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
Do you always send for SDHB by IHC for workup of GIST? or is NGS/FISH that includes SDHB sufficient?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
Are you comfortable using durvalumab + tremelimumab in advanced HCC with portal vein thrombus, when these patients were not included in the HIMALAYA trial?
